FDA D.I.S.C.O. Burst Edition: FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies
0:00
3:30
Listen to a soundcast of the April 17, 2023, FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies.
Otros episodios de "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
No te pierdas ningún episodio de “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)”. Síguelo en la aplicación gratuita de GetPodcast.